BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 BeOne Medicines (
NASDAQ:ONC ) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development.
John Oyler, BeOne’s co-founder, chairman and chief
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets.
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.
HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model Baidu is transitioning from a search-driven advertising company into an AI infrastructure and enterprise cloud provider in China. HHLR’s exit comes as investors weigh whether this transformation will lead to sustainable growth.
Prediction: These 3 Stocks Will Crush the Market in 2026 These stocks all have catalysts on the way that could provide great news for investors.
3 Stocks to Buy in February These three stocks appear to be poised for strong performances in 2026.
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
What's Going On With Summit Therapeutics Stock On Monday? Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.
